UnitedHealth's Misdiagnosis: Can Berkshire's Bet Spark a Recovery?

UnitedHealth Group (UNH) is experiencing significant margin erosion due to severely underestimated medical cost trends, with its cost ratio averaging 87.1% in 1H25 and the full-year EPS outlook slashed to at least $16; earnings growth is not expected before 2026. Amidst this turmoil, including a DOJ criminal investigation into Medicare Advantage billing and potential $1.6 billion in settlement costs, Berkshire Hathaway disclosed a strategic purchase of over 5 million shares, prompting some market buying. However, UNH shares remain down 39.7% year-to-date, reflecting persistent investor concern over rising utilization and regulatory risks that are also impacting industry peers like Centene and Elevance.

Analysis

UnitedHealth Group is confronting a severe operational and financial crisis driven by a significant underestimation of medical cost trends. The company's medical cost ratio has deteriorated sharply, rising from 83.2% in 2023 to an average of 87.1% in the first half of 2025, with projections it could reach 89.4% by year-end. This margin compression directly led to two consecutive quarterly earnings misses and a drastic reduction in its full-year EPS outlook to at least $16 from a prior range of $26–$26.50, with the consensus estimate of $16.21 implying a 41.4% year-over-year decline. Compounding the issue are significant legal and regulatory headwinds, including a Department of Justice criminal investigation into its Medicare Advantage billing practices and $1.6 billion in potential settlement costs. Management has signaled a prolonged turnaround, with the return of a former CEO and guidance that earnings growth is not anticipated before 2026. While Berkshire Hathaway's new $1.57 billion stake provides a notable vote of confidence and suggests a long-term value proposition, the stock's 39.7% year-to-date decline has not eliminated its valuation premium, as it still trades at a forward P/E of 17.87, above the industry average of 14.96. The fact that peers like Centene and Elevance are also slashing guidance confirms this is an industry-wide headwind, though UnitedHealth's challenges appear particularly acute.

Key Decisions for Investors

• Given the severe earnings downgrade, ongoing DOJ investigation, and management's forecast of no growth until 2026, investors should exercise extreme caution, as significant near-term risks and share price volatility are likely to persist.
• For long-term investors with a high risk tolerance, Berkshire Hathaway's investment could be viewed as a signal of deep value, but any position should be sized with the understanding that a recovery is contingent on stabilizing medical costs and resolving major legal issues over a multi-year horizon.
• Closely monitor the quarterly medical cost ratio for signs of stabilization, any official announcements regarding the DOJ investigation, and management's execution on its turnaround plan, as these will be key catalysts for a change in the stock's trajectory.
• Despite the 39.7% YTD price drop, investors should recognize that UNH still trades at a premium to its industry, suggesting further downside is possible if fundamental deterioration continues or if negative legal developments materialize.